

inhibitors *in vitro* and can be used to test drug candidates for their effectiveness against common drug

resistant mutants of HIV-1 RT. Please contact Dr. Hughes directly ([hughes@ncicrf.gov](mailto:hughes@ncicrf.gov)) if you want

additional information about RT expression plasmids that are not listed below.

| Vector                   | Description                  | Reference No. |
|--------------------------|------------------------------|---------------|
| Wild-type HIV-1 RT ..... | full length, wild type ..... | E-034-1991/0  |
| L100I .....              | NNRTI resistant .....        | E-034-1991/1  |
| K103N .....              | NNRTI resistant .....        | E-034-1991/1  |
| V106A .....              | NNRTI resistant .....        | E-034-1991/1  |
| V108I .....              | .....                        | .....         |
| E138K .....              | NNRTI resistant .....        | E-034-1991/1  |
| Y181I .....              | .....                        | .....         |
| Y181C .....              | NNRTI resistant .....        | E-034-1991/1  |
| Y188L .....              | .....                        | .....         |
| Y188H .....              | NNRTI resistant .....        | E-034-1991/1  |
| G190A .....              | .....                        | .....         |
| G190S .....              | .....                        | .....         |
| P236L .....              | NNRTI resistant .....        | E-034-1991/1  |

RTs that carry some combinations of NNRTI mutations, e.g., K103N+Y181I, are also available.

|                           |                                  |              |
|---------------------------|----------------------------------|--------------|
| K65R .....                | NRTI resistant .....             | E-034-1991/2 |
| T69G .....                | .....                            | .....        |
| L74V .....                | NRTI resistant .....             | E-034-1991/1 |
| M184I .....               | Lamivudine (3TC) resistant ..... | .....        |
| M184V .....               | Lamivudine (3TC) resistant ..... | E-034-1991/1 |
| AZT-R (5 mutations) ..... | AZT resistant .....              | E-034-1991/1 |
| Δ67 complex .....         | Multi-NRTI resistant .....       | E-034-1991/4 |
| Q151M .....               | Multi-NRTI resistant .....       | E-034-1991/4 |
| Q151M Complex .....       | Multi-NRTI resistant .....       | E-034-1991/4 |
| SSGR/T215Y .....          | Multi-NRTI resistant .....       | E-034-1991/4 |
| SSSR/T215Y .....          | Multi-NRTI resistant .....       | E-034-1991/4 |

Dated: August 20, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-17517 Filed 9-1-05; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center on Minority Health and Health Disparities; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given by the National Advisory Council on Minority Health and Health Disparities.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Minority Health and Health Disparities.

*Date:* September 20, 2005.

*Closed:* 8:30 a.m. to 10 a.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892.

*Open:* 10:30 a.m. to 5:30 p.m.

*Agenda:* The agenda will include Opening Remarks, Administrative Matters, Director's Report, NCMHD, IC Health Disparities Research Report, NCMHD Program Highlights, and other business of the Council.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892.

*Contact Person:* Donna Brooks, Asst. Director for Administration, National Center on Minority Health and Health Disparities, National Institutes of Health, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20892, 301-435-2135, [brooksd@ncmhd.nih.gov](mailto:brooksd@ncmhd.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when

applicable, the business or professional affiliation of the interested person.

Dated: August 25, 2005.

**Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-17514 Filed 9-1-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Eye Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Eye Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,